Head-To-Head Survey: VivoSim Labs (NASDAQ:VIVS) versus Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) and VivoSim Labs (NASDAQ:VIVS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings and Valuation

This table compares Bio-Techne and VivoSim Labs”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22 billion	9.37	$181.86 million	$1.15	63.14
VivoSim Labs	$130,000.00	30.37	-$13.84 million	($4.47)	-0.05

Bio-Techne has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Bio-Techne and VivoSim Labs, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0	15	2	0	2.12
VivoSim Labs	1	0	0	0	1.00

Bio-Techne currently has a consensus price target of $68.92, indicating a potential downside of 5.08%. Given Bio-Techne’s stronger consensus rating and higher probable upside, research analysts plainly believe Bio-Techne is more favorable than VivoSim Labs.

Profitability

This table compares Bio-Techne and VivoSim Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

Insider & Institutional Ownership

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 1.0% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bio-Techne beats VivoSim Labs on 12 of the 14 factors compared between the two stocks.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.